# Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

> **NCT04937387** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 359 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** FF/VI
- **DRUG:** FF/UMEC/VI
- **DEVICE:** ELLIPTA

## Key facts

- **NCT ID:** NCT04937387
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-29
- **Primary completion:** 2024-08-05
- **Final completion:** 2024-08-05
- **Target enrollment:** 359 (ACTUAL)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04937387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04937387, "Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04937387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*